Inscripta Announces First Commercial Delivery of Its Onyx ™ Digital Genome Engineering Platform and Closes New $ 150 Million Funding
BOULDER, Colorado – (BUSINESS WIRE) – Inscripta, Inc., the digital genome engineering company, today announced the first commercial delivery of its Onyx ™ platform and the closing of a $ 150 million Series E funding round led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc.
Among the first organizations to receive the Onyx platform is GeneMill, a state-of-the-art synthetic biology foundry at the University of Liverpool. “Inscripta’s Onyx is an extraordinarily powerful platform that will enable high throughput genome editing and analysis. It will revolutionize our capabilities in synthetic biology, ”said Professor Douglas Kell, principal investigator of the ALERT 19 funded project of the Biotechnology & Biological Sciences Research Council. competition.
Dr James Johnson, Co-Principal Applicant and Head of the Liverpool GeneMill, added: “We look forward to continuing our close collaboration with the Inscripta team, working together to explore a wide range of genome discovery and engineering research projects. progress with our customers and collaborators around the world. ”
In a 2020 report, the McKinsey Global Institute estimated that 60% of the physical inputs used in manufacturing today could one day be produced organically. Plastics, fuels, drugs and much more could be made through sustainable and planet-friendly organic pipelines, such as yeast fermentation. Already, yeast is used to produce sweeteners, industrial chemicals and medicinal components.
“This is an important milestone for Inscripta, and it follows our mission to empower researchers to realize the full potential of the bioeconomy. GeneMill, and our other early customers, will be key partners in shaping the broad impact of the Onyx platform’s unprecedented scale, performance and accessibility, “said Sri Kosaraju, President and CEO of Inscripta.” In addition From our enthusiasm for the Onyx platform, we see additional future potential with our innovation, which is captured by our intellectual property portfolio of nearly 100 issued US patents. To that end, we are fortunate to have the support of some of the world’s most notable investors who share our enthusiasm for the long-term opportunity to build transformative technology and impactful organization.
In addition to Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc., the Series E funding includes participation from new investors D1 Capital Partners and Durable Capital Partners LP, as well as existing investors Foresite Capital, Counterpoint Global (Morgan Stanley) and JS Capital LLC.
About the Onyx platform
the Onyx platform is the world’s first benchtop system for scalable digital genome engineering and consists of a benchtop instrument, consumables, software and analysis. With a fully automated CRISPR-based workflow, the Onyx platform enables massively parallel and traceable editing of single cells at an unprecedented scale. Customers love Organic Sestina are successfully experimenting with how the Onyx platform dramatically improves the four steps of synthetic biology to accelerate advanced engineering and genome discovery:
- Design genome-wide libraries in just a few clicks using InscriptaDesigner software
- produce millions of precisely edited cells with push-button simplicity on the Onyx instrument using custom Onyx genomic engineering kits
- Test and characterize thousands of modifications in the Onyx cell library with our genotyping assays followed by pooled or isolated phenotyping
- Learn the impact of individual modifications using the same genotyping tests and our InscriptaResolver software
The Onyx platform enables customers to regularly iterate genome engineering cycles with fewer resources, faster than ever before. For more information on the Onyx platform, visit www.inscripta.com/products.
Inscripta is a life science technology company whose mission is to empower researchers to realize the full potential of the bioeconomy. The company is headquartered in Boulder, Colorado, with offices in San Diego and Pleasanton, California, and Copenhagen, Denmark. For more information visit www .inscrip ta .com.